New drug combo aims to prevent transplant complications in blood cancer patients

NCT ID NCT03320642

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma, or related conditions. The main goal was to see if blood cell recovery was safe when itacitinib was added to the usual GVHD prevention regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: itacitinib
What this could lead to: If it works, this could point toward a safer way to prevent graft-versus-host disease after stem cell transplants.
What could go wrong: This was a very early (Phase 1) trial that was terminated early, so results are limited. It may not show clear benefit or safety over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia graft versus host disease hematopoietic and lymphoid system neoplasm Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive mantle cell lymphoma myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

Anschutz Cancer Pavilion - University of Colorado

Aurora, Colorado, 80045, United States
Azienda Ospedaliera San Gerardo Di Monza

Monza, 20900, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii)

Bergamo, 24127, Italy
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu

Nantes, 44093, France
Chru de Lille Hopital Claude Huriez

Lille, 59037, France
Chu Vandoeuvre-Les-Nancy, Hopital Brabois

Vandœuvre-lès-Nancy, 54500, France
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo

Pavia, 27100, Italy
Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Hospital Puerta de Hierro

Majadahonda, 28222, Spain
John Theurer Cancer Center, Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Loyola University Medical Center

Maywood, Illinois, 60153, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
The Ohio State University

Columbus, Ohio, 43210, United States
University of Maryland - Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.